Biomedical AI platform that grounds biopharma R&D decisions in validated biology.
View competitors
Mithrl builds AI infrastructure and biomedical world models for biopharma R&D teams.
Mithrl is an AI infrastructure company for biopharma that deploys a proprietary biomedical world model and agentic harness so R&D teams can reason over validated biology inside their own environment. Co-founded by Vivek Adarsh and Shara Balakrishnan, the San Francisco company helps scientists move from raw omics and experimental data to auditable, program-level decisions.
Its Mithrl-1 platform routes and orchestrates frontier models with token optimization and context grounded in peer-reviewed science plus each client's proprietary data. The company raised a $4 million seed led by Bonfire Ventures in November 2024 and a $20 million Series A led by Obvious Ventures in September 2026, with participation from Headline, AGI House, and pharma executives.

nference
nference.net

LatchBio
latch.bio

Insitro
insitro.com

Lila Sciences
lila.ai

Patronus AI
patronus.ai

Humigent
humigent.ai

Inductive Bio
inductive.bio

Thinking Machines Lab

Transfyr
transfyr.ai

Aether AI
aetherlabs.ai

BioStack Platforms
getbiostack.com

EvolutionaryScale

Inherent
inherentlabs.ai

TypeSafe AI
typesafe.ai

Klavis AI
klavis.ai

Hippocratic AI
hippocraticai.com

Convexia
convexia.bio

Quadrillion
quadrillion.io

Insilico Medicine
insilico.com

Synthetic Sciences
Companies similar to Mithrl include nference, LatchBio, Insitro and Lila Sciences.
Mithrl was founded in 2023.
Mithrl's headquarters is located in San Francisco, CA, US.
Mithrl's most recent funding round was for $20M (USD) in September 2026.
As of Sep 15, 2026, Mithrl has disclosed funding of $24M (USD).
Mithrl has 24 employees as of Sep 16, 2026.